Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock rose 88.76% from a year ago, while it registered a 62.32% increase year-to-date. Based on consensus, Wall Street analysts have assigned a moderate buy rating to Intellia Therapeutics stock, with an average price target of $21.25.

Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple

In a Securities and Exchange Commission (SEC) filing dated April 10, Intellia Therapeutics reported that its Board adopted amendments to the company’s Third Amended and Restated By-laws on April 7. Under the Fourth Amended and Restated By-laws, the company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the company to notify the shareholder of any facially apparent deficiencies in a timely notice.

The biopharmaceutical firm added that the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the company consents in writing to the selection of an alternative forum.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine, leveraging clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.

While we acknowledge the risk and potential of NTLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NTLA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Data Center Stocks to Buy for the Long Term and 5 Stocks with Double Digit Returns.

Disclosure: None. Follow Insider Monkey on Google News.